Korean J Helicobacter Up Gastrointest Res.
2016 Dec;16(4):204-214. 10.7704/kjhugr.2016.16.4.204.
The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study
- Affiliations
-
- 1Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
- 2Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. psheon5132@naver.com
- 3Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
- 4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- 5Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
- 6Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- 7Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
- KMID: 2383561
- DOI: http://doi.org/10.7704/kjhugr.2016.16.4.204
Abstract
- BACKGROUND/AIMS
Despite the efficacy of proton pump inhibitor (PPI) treatment, a considerable number of patients with non-erosive reflux disease (NERD) are resistant to treatment with a PPI at the standard dose. In these patients, doubling the dose of PPI is one of the potential therapeutic strategies. However, only few studies support this therapeutic strategy. The aim of this study was to assess the efficacy and safety of 40 mg esomeprazole once daily in patients with persistent symptoms of NERD despite standard daily PPI therapy.
MATERIALS AND METHODS
A total of 92 patients with NERD who had persistent symptoms of NERD despite standard dose (half dose) of PPI for more than 4 weeks, were enrolled in this multicenter (eight centers) open-label study. Efficacy and safety of a daily dose of 40 mg esomeprazole were evaluated after 4 weeks in all the patients.
RESULTS
The sum score of two symptoms (heartburn and regurgitation) decreased significantly from 72.51 to 32.55 after 4 weeks of treatment (P<0.001). The percentage of patients with ≥50% improvement in symptom score (heartburn+acid regurgitation), during the study period was 66.7%. Patients with severe symptoms at baseline had significantly higher symptom improvement rate in comparison to patients who had milder symptoms. Adverse effects related to the treatment were reported by 3 (3.3%) patients.
CONCLUSIONS
Esomeprazole 40 mg once daily is an effective and safe strategy to treat NERD patients with persistent symptoms despite standard daily PPI therapy.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Double-blind, Randomized, Multicenter Clinical Trial Investigating the Efficacy and Safety of Esomeprazole Single Therapy Versus Mosapride and Esomeprazole Combined Therapy in Patients with Esophageal Reflux Disease
- Therapeutic Response to 20 mg of Esomeprazole Twice Daily in Patients with Gastroesophageal Reflux Disease-related Non-cardiac Chest Pain: An Open-Label Randomized Pilot Study
- Dilated Intercellular Spaces of Esophageal Epithelium in Korean Reflux Esophagitis and Its Reversibility after Esomeprazole Treatment
- Proton Pump Inhibitor for Gastroesophageal Reflux Disease: Intelligent Prescription
- Multicenter Study to Evaluate the Effect of Esomeprozole in Gastro-esophageal Reflux Disease
